India Pharma Industry Faces Raw Material Crunch as Government Restricts Ammonia Supply
Drugmakers warn of API production disruption, medicine shortages and export impact after fertiliser sector gets priority access to surplus ammonia
Hızlı Bakış
- India's pharmaceutical industry faces a potential raw material crunch after the department of fertilizers issued an advisory restricting surplus ammonia sales to the fertiliser sector.
- The directive mandates urea manufacturing units sell surplus ammonia strictly for fertiliser production, prioritising P&K and NPK manufacturers of subsidised fertilisers.
- Pharma executives warn the move could disrupt domestic API production, cause medicine shortages and affect India's export commitments, as ammonia is a critical input with limited alternative sourcing options.
Yapay zekâ özeti
Neden Önemli?
India is a major global pharmaceutical hub, supplying affordable generic medicines to millions worldwide. The country relies heavily on domestic urea plants for ammonia supply, which is essential for synthesizing various APIs, intermediates and formulations. Any disruption to this supply chain could have cascading effects on medicine production and exports.
New Delhi: India's pharmaceutical industry faces a potential raw material crunch after the department of fertilizers issued an advisory restricting the sale of surplus ammonia to the fertiliser sector. The move has raised concern among drugmakers that rely on ammonia as a key input in the production of a wide range of medicines and active pharmaceutical ingredients (APIs).
Industry executives said the directive, if implemented in its current form, could disrupt domestic production, lead to medicine shortages and affect India's export commitments. Pharma cos may face shortage of the key input as the directive restricts sale of surplus ammonia to fertiliser cos.
Namit Joshi, chairman of Pharmexcil, said the diversion of ammonia to the fertiliser sector is a concern. "It will lead to shortages in pharma," he said. "We will seek clarification on this advisory."
The order follows a gazette notification issued by the ministry of petroleum and natural gas on March 9, which requires that natural gas supplied to fertiliser plants be used only for fertiliser production and not diverted. "All urea manufacturing units are directed that its sale must be strictly for fertiliser production in compliance with the Natural Gas (Supply Regulation) Order, 2026. Its sale must be prioritised to P&K/NPK manufacturers of subsidised fertilisers at reasonable price," the advisory said.
The advisory came after reports that some urea units had issued open tenders to sell ammonia outside the fertiliser sector, while P&K producers faced shortages and high prices. An industry executive said the pharmaceutical sector depends heavily on ammonia for the synthesis of several APIs, intermediates and formulations. "This is going to hurt us badly," said a senior executive at a mid-sized API manufacturer, requesting anonymity. "We have been sourcing ammonia from urea plants for years. If that channel is shut down, we will have no immediate alternative."
Pharma exporters are particularly concerned that prolonged ammonia shortages could lead to production cuts, delays in order fulfilment and strain long-standing relationships with overseas buyers. "Any disruption at the input stage can have a cascading effect down the supply chain," added another executive.
Bundan Sonra Ne Olabilir?
Yapay zekâ öngörüsü — kesinlik taşımaz
Pharmexcil will likely meet with government officials to seek exemptions or modified terms for pharmaceutical ammonia usage
Çok muhtemel · Haftalar içinde
Alternative ammonia sourcing arrangements may be explored by pharmaceutical companies
Muhtemel · Aylar içinde
Potential production cuts in API manufacturing if restrictions persist
Olası · Aylar içinde
Açık Sorular
- What specific alternatives can pharma companies use for ammonia sourcing?
- How long will the restriction last?
- Will the government provide any exemptions for pharmaceutical usage?
- What will be the exact impact on specific medicines?
